awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33400687-5DEEFDB4-429A-41E9-A457-9055A3753FB2
Q33400687-5DEEFDB4-429A-41E9-A457-9055A3753FB2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-5DEEFDB4-429A-41E9-A457-9055A3753FB2
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
P2860
Q33400687-5DEEFDB4-429A-41E9-A457-9055A3753FB2
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-5DEEFDB4-429A-41E9-A457-9055A3753FB2
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a73d9bec6f9d2860c6583787af06bcace446846e
P2860
Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.